

Special Issue

Antibody Immunity against Emerging Pathogens

Message from the Guest Editors

Emerging infections are a global health concern, and antibodies produced by the body fight invading pathogens. Antibodies have different mechanisms, can be antigen-specific, and are used to evaluate immune statuses. However, antibodies can also exacerbate disease severity and hinder vaccine development. This Special Issue aims to explore and understand the roles of antibodies in emerging and re-emerging viral infections, including profiling humoral responses, protective mechanisms, molecular mechanisms, improved strategies, therapeutic advances, and cross-reactive immunity. The objective is to delve into the following aspects in detail:

- Characterization of humoral responses during viral, bacterial or fungal infections.
- Identification of new protective mechanisms of antibodies during acute and chronic infections.
- Study of the molecular mechanisms of autoantibodies that worsen microbial infections.
- Advancements in strategies to elicit antibody responses through vaccination.
- Recent developments in therapeutic antibodies against microbial infections.
- Analysis of cross-reactive immunity following infection and vaccination.

Guest Editors

Dr. Fok Moon Lum

A*STAR Infectious Diseases Labs (ID Labs), Singapore, Singapore

Dr. Siew-Wai Fong

A*STAR Infectious Diseases Labs (ID Labs), Singapore, Singapore

Deadline for manuscript submissions

closed (31 January 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/195570

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).